|
WO2011009082A2
|
|
Compositions comprising human rhbdf1-modulating nucleic acids and methods of use
|
|
WO2011005980A1
|
|
Novel heterobifunctional polyethylene glycol reagents, their preparation and uses thereof
|
|
WO2009152346A2
|
|
Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof
|
|
EP2285959A2
|
|
Compositions comprising cmyc sirna and methods of use thereof
|
|
WO2009143372A2
|
|
Compositions comprising a-raf, b-raf, and c-raf sirna and methods of use thereof
|
|
WO2009143371A2
|
|
COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF
|
|
WO2009143281A2
|
|
Compositions comprising c-met sirna and methods of use thereof
|
|
WO2009143277A2
|
|
Compositions comprising hscn9a sirna and methods of use thereof
|
|
US2011105588A1
|
|
Compositions comprising notch1 sirna and methods of use thereof
|
|
WO2009114724A2
|
|
COMPOSITIONS COMPRISING NUCLEAR FACTOR-KAPPA B (NF-ĸB) SIRNA AND METHODS OF USE
|
|
WO2009114476A1
|
|
Compositions comprising survivin sirna and methods of use thereof
|
|
US2011065644A1
|
|
Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
|
|
EP2209834A2
|
|
Heterobifunctional polyethylene glycol reagents
|
|
US2010210710A1
|
|
THERAPEUTIC siRNA MOLECULES FOR REDUCING VEGFR1 EXPRESSION IN VITRO AND IN VIVO
|
|
US2010280097A1
|
|
Compositions comprising hif-1 alpha sirna and methods of use thereof
|
|
CA2704737A1
|
|
Compositions comprising k-ras sirna and methods of use
|
|
US2010273858A1
|
|
Compositions comprising stat5 sirna and methods of use thereof
|
|
EP2190994A2
|
|
Compositions comprising stat3 sirna and methods of use thereof
|
|
US2010279919A1
|
|
Compositions comprising human integrin-linked kinase-sirna and methods of use thereof
|
|
EP2170351A2
|
|
Methods and compositions for treatment of cancer and other angiogenesis - related diseases
|
